GSMA: US Gets Set To Clash with Europe at WRC-19
24.10.2019 10:00:00 EEST | Business Wire | Press release
A clash between the US and Europe over 5G’s future development at The World Radiocommunication Conference 2019 (WRC-19) – taking place in Egypt from 28 October to 22 November 2019 – could risk $565bn of economic expansion globally over the next 15 years, warned the GSMA today.
This economic growth from next-generation 5G services depends on the availability of a specific strand of radio frequencies, known as ‘millimetre wave’ frequencies, which are set to be identified for use by mobile operators at WRC-19. However, efforts by Europe to constrain the use of these critical frequencies due to claims of potential interference with some space services has 5G’s future hanging in the balance.
“The stakes are high - a new generation of 5G services and the economic growth accompanying them will depend on the spectrum decisions taken at WRC-19,” said Brett Tarnutzer, Head of Spectrum, GSMA. “We are calling for Europe to join the US in taking a pro-5G stance at WRC-19 to protect its digital future. Some administrations are still determined to limit mobile use of airwaves that 5G requires to reach its full potential. This protectionist attitude will have consequences for our global economy if allowed to prevail.”
“Our focus is on ensuring that all regions are on board with the win-win resolution that will allow for robust 5G deployments globally while protecting satellite interests worldwide,” said Tom Power, Senior Vice President & General Counsel, CTIA. “Reports indicate that the fastest 5G peak speeds today are in the US, and that’s because the US was the first to deploy mmWave. The benefits of using this spectrum are clear but only through global harmonization at WRC-19 will all regions gain the greatest value.”
Benefits of mmWave spectrum
mmWave bands are critical to providing ultra-high speeds and ultra-high capacity for a wide range of consumer, business and government services that require almost instantaneous delivery of large amounts of data. This includes entertainment services such as downloading ultra-high definition movies in seconds, virtual and augmented reality applications, remote surgery with ‘haptic’ feedback, precise control of industrial devices and robots, and autonomous vehicles.
Three thousand delegates from over 190 nations will meet at WRC-19 to agree on how this spectrum may be used. Different countries may have different approaches and strategies, but WRC is the meeting point for all nations to maximize the potential for 5G within their borders by thinking globally. The process of harmonization at WRC-19 delivers global roaming and economies of scale for vendors and carriers, and that translates into lower costs, faster deployments and greater convenience for consumers.
Clash over airwaves at WRC-19
The build-up to WRC-19 is a four-year process and the use of mmWave spectrum has been the subject of intense technical study throughout. WRC-19 is the final decision after a lot of analysis and technical study.
Technical studies supported by the Americas, Africa and Arab states, have demonstrated that 5G using mmWave spectrum can co-exist safely and efficiently alongside weather-sensing services, commercial satellite services and others. These were conducted within the ITU, a UN agency. In the US, the FCC developed emission limits on 5G to protect weather sensors in nearby spectrum bands. Ahead of WRC-19, the FCC and the State Department also worked with regulators from other countries throughout the Americas, achieving consensus at the CITEL conference in Ottawa in August.
Despite this body of evidence, European countries are looking to limit the use of mmWave spectrum by setting protective technical conditions.
“It is important to follow studies which make realistic assumptions about how networks will function and make the best use of the spectrum for all,” added Brett Tarnutzer. This approach is being followed in the Americas, Africa and the Middle East but we need to find a global solution, including Europe. Large ‘guard bands’ will be needed – that is empty tranches of unused spectrum separating services - if we have technical limits which are too severe. This will restrict the economic benefit we can gain from finite spectrum resources and harm consumers and industry.”
-ENDS-
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators with over 350 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.
For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191024005025/en/
Contact information
Media Contacts:
For the GSMA
Gearóid Cashman
+44 79 7679 0169
gcashman@webershandwick.com
GSMA Press Office
pressoffice@gsma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
